Thousands of NHS patients in England with several sclerosis (MS) will soon be offered “taking home” to manage their condition, leaving the hospital tour for injection or infection.

Drug advisory body Nice says that Claderibin can help people with the active relaxing-remariting version of the disease, as well as more severe, highly active MS, for which it has already been used.

Experts say that access to the drug should give freedom to patients more than the hospital and free the clinic time.

NHS is the first healthcare system in Europe to roll treatment.

NICE is expected to release final guidance to England in April, with access to Wales and North Ireland. Scotland is also considering this.

More than 150,000 people live with MS – a condition that affects the brain and spinal cord in Britain.

Although it cannot be cured at present, treatment may slow down the disease and reduce symptoms.

Trials show that cladribin can reduce the number and severity of relaxes.

The drug targets some immune cells involved in inflammation and myelin damage in MS.

This is given in addition to 12 months in two treatment courses, which means that the patient will take about 20 pills at home.

The list price is approximately £ 2,000 per tablet, but it is not clear how much NHS is paying because it can interact with drug companies.

It is estimated that about 2,000 patients may be offered treatment in the first three years.

Clare Elgar, 37, Southampton’s 37 -year -old, took a cladibine for his relaxing MS, which was diagnosed in January 2021 after working in his right hand and experienced loss of numbness on his face.

Clare says: “Being able to treat at home meant that I could maintain my day-to-day routine and do not travel to the hospital. I am thrilled that new norms will now give others the opportunity to benefit from this life-changing medicine.”

Laura Thomas, head of the policy at the MS Society, said: “This decision can be specially benefited by those who struggle to go to the hospital regularly, such as young working age adults.”

It will also benefit patients considering starting a family, as it is safe to be pregnant after six months of the final course of treatment – which is less restrictive than many other options – according to Ms. Thomas.

“We are very happy that more people with MS will now be able to choose an effective treatment that conforms to their lifestyle.”